美国食品药品监督管理局批准了激酶抑制剂维姆塞替尼 (Romvimza，Deciphera Pharmaceuticals, LLC)，用于治疗手术切除可能会导致功能限制恶化或严重发病的有症状腱鞘巨细胞瘤 (TGCT) 成年患者。

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook from investment analysts with a target price significantly lower than its market price. Collegium Pharmaceutical, Inc. (COLL) is perceived as ...

High Prevalence of Malnutrition in Geriatric Patients With Solid Organ Cancer—An Institutional Study The incidence of EC was analyzed from 2010 to 2015 using data from Brazilian Population–Based ...

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of ...

Cortellis does not show forecasts for vimseltinib. Vimseltinib was initially discovered by Deciphera Pharmaceuticals. Ono acquired Deciphera — and its portfolio of kinase inhibitors — last ...

The company’s pipeline concentrates on creating treatments for diseases such as Alzheimer’s and Huntington’s. Credit: Art_Photo/Shutterstock. Trimtech Therapeutics has closed a seed funding round of ...

The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono.

The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology. FDA trial start clearances are usually ...

This page features the latest news about the Deciphera Pharma stock. C4 Therapeutics stock plunges to 52-week low at $2.92 C4 Therapeutics Inc. shares have tumbled to a 52-week low, with the stock ...